A Phase 3 interventional study of Placebo and Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by United Therapeutics. Completed at 96 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 13th largest by enrollment of the 188 interventional ones that give a count, is one of 9 that started in 2021, is one of 37 in phase 3, and was the 160th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Oorja Bio, Inc. · Sites in United States
Ages 40+
University of California, San Francisco · Sites in United States
Ages 18+
Trevi Therapeutics · Sites in United States
Ages 40+
Joseph C. Wu · Sites in United States
Ages 40+
Chiesi Farmaceutici S.p.A. · Sites in United States, North Macedonia, Korea, Republic of and 1 more country
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 89 · Phase 3 39 · Phase 4 6
First in 1999; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 598 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 61 across the 188 interventional studies, 320 across the 45 observational. Of the 170 that completed or were terminated, 86 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 236 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.
United Therapeutics has 4 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
15 of the studies in Idiopathic Pulmonary Fibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07868419Phase 3Trevi TherapeuticsIdiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | 2027-08 |
| NCT06736990Calluna Pharma ASA Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | 2026-11 |
| NCT06853145University of VirginiaHyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis | 2026-12 |
| NCT03478553University of Colorado, DenverThe Genetics of Pulmonary Fibrosis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Study RIN-PF-301 is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute FVC in subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo. All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths QID. Study drug doses may be titrated up as tolerated, until the target dose or maximum clinically tolerated dose is achieved. Once eligible, 6 Treatment Period visits to the clinic will be required at Weeks 4, 8, 16, 28, 40, and 52.
Efficacy assessments include spirometry (FVC), time to clinical worsening, time to first acute exacerbation of IPF, overall survival, King's Brief Interstitial Lung Disease (K-BILD) questionnaire, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration, supplemental oxygen use, and lung diffusion capacity (DLCO). Safety assessments include the development of adverse events (AEs)/serious adverse events (SAEs), vital signs, clinical laboratory parameters, and electrocardiogram (ECG) parameters.
Subjects who complete the Week 52 Visit may be offered the opportunity to enter an open-label extension (OLE) study after completing the final study visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching placebo inhaled using an ultrasonic nebulizer QID
Drug: Placebo · Device: Treprostinil Ultrasonic Nebulizer
Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
Drug: Inhaled Treprostinil · Device: Treprostinil Ultrasonic Nebulizer
Placebo administered QID
Inhaled treprostinil (6 mcg/breath) administered QID
Also known as: Tyvaso
Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Change in Absolute FVC From Baseline to Week 52
The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.
Time frame: Baseline to Week 52
Time to Clinical Worsening
Clinical worsening was monitored from randomization until 1 of the following criteria were met: death (all causes), hospitalization due to a respiratory indication, or 10% relative decline in % predicted FVC. The number of participants with clinical worsening was reported. The time to first clinical worsening event was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.
Time frame: Baseline to Week 52
Time to First Acute Exacerbation of IPF
An acute exacerbation of IPF is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality. The number of participants with an exacerbation of IPF was reported. The time to first acute exacerbation of IPF was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.
Time frame: Baseline to Week 52
Overall Survival at Week 52
Vital status was assessed for all subjects at Week 52, including those who discontinued the study prematurely. The number of deaths by Week 52 was reported. The time to death was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables. Note: Participants who discontinued from the study early had their time to death censored at Day 373 or last contact date when known to be alive (whichever occurred first), and participants with lung transplantation had their time to death censored at lung transplant date. Therefore, the number of deaths for this outcome measure differ from the overall number on deaths (reported in the Adverse Events section).
Time frame: Week 52
Change in % Predicted FVC From Baseline to Week 52
The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. Percent predicted FVC is calculated based on factors such as ethnicity, sex, age, height, and weight.
Time frame: Baseline to Week 52
Change in K-BILD Questionnaire Score From Baseline to Week 52
The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) is a self-administered, 15-item questionnaire validated for patients with interstitial lung disease (ILD) consisting of 3 domains (breathlessness and activities, psychological, and chest symptoms). Each of the 15 questions is scored from 1 (worst score) to 7 (best score). The scores for the 15 questions are added together and converted into a Total Score from 0 to 100. Higher scores indicate a better quality of life.
Time frame: Baseline to Week 52
Change in DLCO From Baseline to Week 52
The DLCO measurement measures how well oxygen moves from the lungs to the blood.
Time frame: Baseline to Week 52
| Milestone | Inhaled Treprostinil | Placebo |
|---|---|---|
| Started | 299 | 299 |
| Completed | 218 | 216 |
| Not completed | 81 | 83 |
| Withdrew: Adverse event | 19 | 22 |
| Withdrew: Death | 8 | 14 |
| Withdrew: Progressive disease | 1 | 5 |
| Withdrew: Lung transplantation | 6 | 6 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Physician decision | 5 | 4 |
| Withdrew: Withdrawal by subject | 38 | 31 |
| Withdrew: Unable to attend final visit | 1 | 0 |
The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.
| mL | Inhaled Treprostinil | Placebo |
|---|---|---|
| Change in Absolute FVC From Baseline to Week 52 | -43.3 (-92.1 to -9.1) | -196.2 (-227.1 to -155.6) |
Clinical worsening was monitored from randomization until 1 of the following criteria were met: death (all causes), hospitalization due to a respiratory indication, or 10% relative decline in % predicted FVC. The number of participants with clinical worsening was reported. The time to first clinical worsening event was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.
| Participants | Inhaled Treprostinil | Placebo |
|---|---|---|
| Time to Clinical Worsening | 95 | 133 |
An acute exacerbation of IPF is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality. The number of participants with an exacerbation of IPF was reported. The time to first acute exacerbation of IPF was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.
| Participants | Inhaled Treprostinil | Placebo |
|---|---|---|
| Time to First Acute Exacerbation of IPF | 10 | 19 |
Vital status was assessed for all subjects at Week 52, including those who discontinued the study prematurely. The number of deaths by Week 52 was reported. The time to death was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables. Note: Participants who discontinued from the study early had their time to death censored at Day 373 or last contact date when known to be alive (whichever occurred first), and participants with lung transplantation had their time to death censored at lung transplant date. Therefore, the number of deaths for this outcome measure differ from the overall number on deaths (reported in the Adverse Events section).
| Participants | Inhaled Treprostinil | Placebo |
|---|---|---|
| Overall Survival at Week 52 | 22 | 32 |
The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. Percent predicted FVC is calculated based on factors such as ethnicity, sex, age, height, and weight.
| percentage of predicted | Inhaled Treprostinil | Placebo |
|---|---|---|
| Change in % Predicted FVC From Baseline to Week 52 | -1.4 (-2.5 to -0.3) | -5.4 (-6.2 to -4.7) |
The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) is a self-administered, 15-item questionnaire validated for patients with interstitial lung disease (ILD) consisting of 3 domains (breathlessness and activities, psychological, and chest symptoms). Each of the 15 questions is scored from 1 (worst score) to 7 (best score). The scores for the 15 questions are added together and converted into a Total Score from 0 to 100. Higher scores indicate a better quality of life.
| scores on a scale | Inhaled Treprostinil | Placebo |
|---|---|---|
| Change in K-BILD Questionnaire Score From Baseline to Week 52 | -1.1 (-2.1 to 0.0) | -2.4 (-3.8 to -1.2) |
The DLCO measurement measures how well oxygen moves from the lungs to the blood.
| mmol/min/kPa | Inhaled Treprostinil | Placebo |
|---|---|---|
| Change in DLCO From Baseline to Week 52 | -0.3 (-0.4 to -0.1) | -0.3 (-0.4 to -0.2) |
Collected over Adverse events (AEs) were recorded throughout the course of the study from the time that each subject signed the ICF until the time screen failure was documented, or until the subject withdrew consent and discontinued from the study; or until resolution, until judged by the Investigator to no longer be clinically significant, or for at least 30 days beyond the final study visit at Week 52 study for up to an average of 56 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Treprostinil | 22/299 (7.4%) | 54/299 (18.1%) | 287/299 (96%) |
| Placebo | 34/299 (11.4%) | 72/299 (24.1%) | 280/299 (93.6%) |
| Event | Inhaled Treprostinil | Placebo |
|---|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 9/299 | 14/299 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 7/299 | 14/299 |
| PneumoniaInfections and infestations | 10/299 | 6/299 |
| InfluenzaInfections and infestations | 0/299 | 4/299 |
| SyncopeNervous system disorders | 4/299 | 1/299 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/299 | 4/299 |
| Chest painGeneral disorders | 3/299 | 1/299 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 3/299 | 1/299 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/299 | 3/299 |
| Cardiac failure congestiveCardiac disorders | 2/299 | 2/299 |
| Event | Inhaled Treprostinil | Placebo |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 164/299 | 99/299 |
| HeadacheNervous system disorders | 91/299 | 48/299 |
| DiarrheaGastrointestinal disorders | 49/299 | 63/299 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 56/299 | 47/299 |
| FatigueGeneral disorders | 47/299 | 45/299 |
| DizzinessNervous system disorders | 44/299 | 36/299 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 42/299 | 16/299 |
| COVID-19Infections and infestations | 25/299 | 39/299 |
| NauseaGastrointestinal disorders | 33/299 | 37/299 |
| Upper respiratory tract infectionInfections and infestations | 36/299 | 29/299 |
| Age, Continuous(years) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Median | 73.0 (52 to 91) | 74.0 (53 to 89) | 73.0 (52 to 91) |
| Sex: Female, Male(Participants) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Female | 71 | 65 | 136 |
| Male | 228 | 234 | 462 |
| Race (NIH/OMB)(Participants) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 14 | 11 | 25 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 5 | 6 | 11 |
| White | 270 | 271 | 541 |
| More than one race | 1 | 4 | 5 |
| Unknown or Not Reported | 7 | 5 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 17 | 30 |
| Not Hispanic or Latino | 279 | 276 | 555 |
| Unknown or Not Reported | 7 | 6 | 13 |
| Time Since IPF Diagnosis(years) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Median | 2.920 (0.09 to 21.39) | 2.750 (0.08 to 21.03) | 2.830 (0.08 to 21.39) |
| Background Therapy at Randomization(Participants) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| No Background therapy | 68 | 66 | 134 |
| Nintedanib | 132 | 143 | 275 |
| Pirfenidone | 99 | 90 | 189 |
| Forced Vital Capacity (FVC)(mL) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Median | 2626.0 (1019 to 6375) | 2645.5 (1067 to 5065) | 2636.0 (1019 to 6375) |
| % Predicted FVC(percentage of predicted) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Median | 72.40 (39.0 to 128.3) | 72.75 (43.9 to 122.7) | 72.60 (39.0 to 128.3) |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2021 to primary completion in Feb 2026, 57 months.
Results were first posted in Nov 2026, 9 months after primary completion.
Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's 57 months is above that.
Start moved once since we started tracking on Sep 25, 2026: Jun 2021 → Apr 2021, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Idiopathic Pulmonary Fibrosis →